Article info

Download PDFPDF
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Authors

  1. Correspondence to Associate Professor Mandana Nikpour, University of Melbourne, Melbourne, VIC 3065, Australia; m.nikpour{at}unimelb.edu.au
View Full Text

Citation

Oon S, Huq M, Golder V, et al
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Publication history

  • Received September 11, 2018
  • Revised December 17, 2018
  • Accepted January 3, 2019
  • First published January 24, 2019.
Online issue publication 
April 12, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.